JP2014515364A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515364A5 JP2014515364A5 JP2014511862A JP2014511862A JP2014515364A5 JP 2014515364 A5 JP2014515364 A5 JP 2014515364A5 JP 2014511862 A JP2014511862 A JP 2014511862A JP 2014511862 A JP2014511862 A JP 2014511862A JP 2014515364 A5 JP2014515364 A5 JP 2014515364A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- phenyl
- alkoxy
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 173
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 43
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 239000003112 inhibitor Substances 0.000 claims 27
- 125000004452 carbocyclyl group Chemical group 0.000 claims 25
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 21
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- -1 cyano, hydroxyl Chemical group 0.000 claims 13
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 238000001514 detection method Methods 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000003302 alkenyloxy group Chemical group 0.000 claims 10
- 125000005133 alkynyloxy group Chemical group 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 125000004001 thioalkyl group Chemical group 0.000 claims 10
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 9
- 208000012902 Nervous system disease Diseases 0.000 claims 8
- 208000025966 Neurological disease Diseases 0.000 claims 7
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000037259 Amyloid Plaque Diseases 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 210000005013 brain tissue Anatomy 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000012216 imaging agent Substances 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000013498 tau Proteins Human genes 0.000 claims 3
- 108010026424 tau Proteins Proteins 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 208000023697 ABri amyloidosis Diseases 0.000 claims 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 238000001506 fluorescence spectroscopy Methods 0.000 claims 1
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 claims 1
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
- XHIKZWOEFZENIX-GOSISDBHSA-N CCCOc1ccc([C@@H](CNC2=O)N2c(cc2)cc3c2[nH]cn3)cc1 Chemical compound CCCOc1ccc([C@@H](CNC2=O)N2c(cc2)cc3c2[nH]cn3)cc1 XHIKZWOEFZENIX-GOSISDBHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490654P | 2011-05-27 | 2011-05-27 | |
| US61/490,654 | 2011-05-27 | ||
| PCT/EP2012/059649 WO2012163773A1 (en) | 2011-05-27 | 2012-05-24 | Radiolabelled glutaminyl cyclase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515364A JP2014515364A (ja) | 2014-06-30 |
| JP2014515364A5 true JP2014515364A5 (enExample) | 2015-06-25 |
Family
ID=46149465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511862A Pending JP2014515364A (ja) | 2011-05-27 | 2012-05-24 | 放射能標識グルタミニルシクラーゼ阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8945510B2 (enExample) |
| EP (1) | EP2714098A1 (enExample) |
| JP (1) | JP2014515364A (enExample) |
| KR (1) | KR20140028076A (enExample) |
| CN (1) | CN103561776B (enExample) |
| AU (1) | AU2012264951A1 (enExample) |
| BR (1) | BR112013030341A2 (enExample) |
| CA (1) | CA2835014A1 (enExample) |
| EA (1) | EA028533B1 (enExample) |
| IL (1) | IL229187A (enExample) |
| MX (1) | MX2013013946A (enExample) |
| SG (2) | SG194770A1 (enExample) |
| WO (1) | WO2012163773A1 (enExample) |
| ZA (1) | ZA201308329B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6454651B2 (ja) | 2013-03-15 | 2019-01-23 | プロビオドルグ エージー | 新規阻害剤 |
| CN104230778B (zh) * | 2014-07-14 | 2017-01-04 | 大连大学 | β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法 |
| CR20170076A (es) | 2014-08-04 | 2017-06-26 | Nuevolution As | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| CA3106239A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| KR102230832B1 (ko) * | 2019-06-17 | 2021-03-24 | (주) 메디프론디비티 | N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2020408107B2 (en) | 2019-12-20 | 2026-04-23 | Nuevolution A/S | Compounds active towards nuclear receptors |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| EP4126874A1 (en) | 2020-03-31 | 2023-02-08 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1250834B (enExample) | 1963-01-09 | |||
| US5304367A (en) * | 1990-11-16 | 1994-04-19 | New York University | In vivo brain imaging agent and method for diagnosis of psychiatric disorders |
| US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| KR101099206B1 (ko) * | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| EP2021340B1 (en) | 2006-04-21 | 2014-07-23 | The Government Of The United States, As Represented by The Secretary Of Health And Human Services | Beta-amyloid pet imaging agents |
| US8278345B2 (en) * | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5677297B2 (ja) * | 2008-07-31 | 2015-02-25 | プロビオドルグ エージー | 神経変性疾患の診断／予後判定の指標としてのグルタミニルシクラーゼ |
| SG193828A1 (en) | 2008-09-04 | 2013-10-30 | Probiodrug Ag | Novel inhibitors |
| EP2411057B1 (en) | 2009-03-23 | 2020-05-06 | Eli Lilly and Company | Imaging agents for detecting neurological disorders |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| US8269019B2 (en) * | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
-
2012
- 2012-05-24 JP JP2014511862A patent/JP2014515364A/ja active Pending
- 2012-05-24 MX MX2013013946A patent/MX2013013946A/es unknown
- 2012-05-24 EA EA201301334A patent/EA028533B1/ru not_active IP Right Cessation
- 2012-05-24 CN CN201280025603.6A patent/CN103561776B/zh not_active Expired - Fee Related
- 2012-05-24 SG SG2013081567A patent/SG194770A1/en unknown
- 2012-05-24 US US13/479,826 patent/US8945510B2/en not_active Expired - Fee Related
- 2012-05-24 BR BR112013030341A patent/BR112013030341A2/pt not_active IP Right Cessation
- 2012-05-24 AU AU2012264951A patent/AU2012264951A1/en not_active Abandoned
- 2012-05-24 EP EP12723476.3A patent/EP2714098A1/en not_active Withdrawn
- 2012-05-24 SG SG10201604304RA patent/SG10201604304RA/en unknown
- 2012-05-24 KR KR20137033449A patent/KR20140028076A/ko not_active Withdrawn
- 2012-05-24 WO PCT/EP2012/059649 patent/WO2012163773A1/en not_active Ceased
- 2012-05-24 CA CA 2835014 patent/CA2835014A1/en not_active Abandoned
-
2013
- 2013-10-31 IL IL229187A patent/IL229187A/en not_active IP Right Cessation
- 2013-11-06 ZA ZA2013/08329A patent/ZA201308329B/en unknown
-
2014
- 2014-12-15 US US14/570,350 patent/US9610368B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6681498B2 (ja) | 重水素化ヘテロ環式化合物及びイメージング剤としてのその使用 | |
| RU2448106C2 (ru) | Новые гетероарил-замещенные бензотиазолы | |
| JP2009528271A5 (enExample) | ||
| ES2584653T3 (es) | Sonda para la obtención de imágenes de Tau | |
| BRPI0617151B8 (pt) | composto, multímero, composto vetorizado, complexo do referido composto, bem como composições farmacêutica, farmacêutica lipídica e de diagnóstico para imagiologia por ressonância magnética e processo para a preparação de um complexo metálico | |
| MY165906A (en) | Phenothiazine diaminium salts and their use | |
| ES2675301T3 (es) | Heteroarilamidas como inhibidores de la agregación de proteínas | |
| AU2003261834A1 (en) | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein | |
| JP2019500352A5 (enExample) | ||
| JP2017521387A5 (enExample) | ||
| JP2018524403A5 (enExample) | ||
| JP2012514007A5 (enExample) | ||
| JP2013504544A5 (enExample) | ||
| JP2013521325A5 (enExample) | ||
| JPWO2005016888A1 (ja) | アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤 | |
| EP2642998A4 (en) | NON-RETINOIDER RBP4 ANTAGONIST FOR THE TREATMENT OF AGE-RELATED MACULAR AGENCY AND MORBUS STARGARDT | |
| JP2014515364A (ja) | 放射能標識グルタミニルシクラーゼ阻害剤 | |
| CA2680157A1 (en) | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes 709 | |
| JP2010520276A5 (enExample) | ||
| RU2016112547A (ru) | Имидазо[1,2-а]пиридин-7-амины в качестве средств визуализации | |
| EP1655287A1 (en) | Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change | |
| Levigoureux et al. | Binding of the PET radiotracer [18F] BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice | |
| KR101854228B1 (ko) | 신규 아밀로이드 친화성 화합물 | |
| CN101293878B (zh) | 苯并噻唑苯胺类化合物及其制备方法和应用 | |
| US20180036433A1 (en) | Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers |